Steve Ward Named Executive VP and CFO at Perosphere Technologies

Perosphere Technologies has welcomed aboard a new member of its top management team, appointing Steve Ward as executive vice president and chief financial officer (CFO).

“We are honored to welcome Steve Ward to our expanding executive team as our new chief financial officer,” Perosphere CEO Sasha H. Bakhru, Ph.D., said. “He brings his extensive experience and strategic mindset to Perosphere at a critical juncture as we begin our commercialization efforts, look to expand worldwide, and drive long term value for our stakeholders. We are confident in Steve’s leadership as we pursue making a difference at the bedside with innovative diagnostic tools for patients.”
 
Ward brings extensive experience and a proven track record in establishing and growing companies, both in and out of the medical device industry. He is a leader in strategic planning, developing financial systems technology to meet shifting needs, working with venture capital, and more. Ward most recently worked as CFO of Viscogliosi Brothers LLC and Viscogliosi Brothers Acquisition Corp. Prior to that, he was the CFO of Paradigm Spine, CFO and chief operating officer of Small Bone Innovations, Vice President of Finance & Administration at ITC, which launched the Hemochron system for warfarin monitoring, and in various capacities with Howmedica Stryker and KPMG. He has both graduate and undergraduate degrees from Fairleigh Dickinson University.
 
“I am very excited to get to work with the Perosphere team, which has developed a game-changing coagulation instrument,” Ward said. “I look forward to contributing to the company’s overall goal of advancing the quality of patient care through innovative diagnostic tools. My previous experience supporting companies through commercialization, and establishing financial controls and excellence in operations makes me uniquely suited to help Perosphere scale, expand, and deliver on its mission to create solutions for patients and healthcare providers.”
 
Perosphere Technologies develops and commercializes its PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including DOACs, according to the company. The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes, Perosphere Technologies claims. The PoC Coagulometer has a CE Mark in the EU but is not yet cleared in the United States.